| __timestamp | Halozyme Therapeutics, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 2652041 |
| Thursday, January 1, 2015 | 40028000 | 2361587 |
| Friday, January 1, 2016 | 45853000 | 4472869 |
| Sunday, January 1, 2017 | 53816000 | 5030957 |
| Monday, January 1, 2018 | 60804000 | 4988941 |
| Tuesday, January 1, 2019 | 77252000 | 5196412 |
| Wednesday, January 1, 2020 | 45736000 | 6652774 |
| Friday, January 1, 2021 | 50323000 | 18418247 |
| Saturday, January 1, 2022 | 143526000 | 24827066 |
| Sunday, January 1, 2023 | 149182000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining financial health. Over the past decade, Halozyme Therapeutics, Inc. and Opthea Limited have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Halozyme's SG&A expenses surged by over 300%, peaking in 2023, while Opthea's expenses increased by approximately 150% during the same period. Notably, Halozyme's expenses in 2023 were nearly 3.5 times higher than Opthea's, highlighting a significant divergence in financial strategies. Despite the absence of data for Halozyme in 2024, Opthea's expenses showed a decline, suggesting a potential shift towards cost efficiency. This analysis underscores the importance of strategic financial management in the biotech sector, where balancing innovation with operational costs can define a company's success.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Opthea Limited
Regeneron Pharmaceuticals, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
BeiGene, Ltd. or Opthea Limited: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Catalent, Inc. vs Halozyme Therapeutics, Inc.
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.